Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...

For every man who has cut carbs from his diet and dropped 10 pounds, there’s a woman who’s done exactly the same thing ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...